ELSEVIER

Atherosclerosis 128 (1997) 267–269

ATHEROSCLEROSIS

Author index

Volume 128 (1997)

Abe, S., see Nakamura, M. **128**, 149
Adejuwon, C.A., see Ezenwaka, C.E. **128**, 201
Akanji, A.O., see Ezenwaka, C.E. **128**, 201
Akanji, B.O., see Ezenwaka, C.E. **128**, 201
Amberger, A., see Schett, G. **128**, 27
Angel, A., see Ren, S. **128**, 1
Antikainen, M., see Knudsen, P. **128**, 165
Assmann, G., see Bruckert, E. **128**, 121
Assmann, G., see Knudsen, P. **128**, 165
Aviram, M., see Hussein, O. **128**, 11

Baoutina, A., see Garner, B. **128**, 47
Baumstark, M.W., see Halle, M. **128**, 235
Ben-Naim, M., see Friedman, G. **128**, 67
Bensadoun, A., see Knudsen, P. **128**, 165
Ben-Yehuda, A., see Friedman, G. **128**, 67
Berg, A., see Halle, M. **128**, 235
Bergeron, J., see Vohl, M.-C. **128**, 183
Beucler, I., see Bruckert, E. **128**, 121
Blann, A.D., G.Y.H. Lip, Hypothesis: is soluble P-selectin a new marker of platelet activation? **128**, 135
Bouchard, C., see Vohl, M.-C. **128**, 183
Braesen, J.H., see Harsch, M. **128**, 139
Bruckdorfer, K.R., see Calzada, C. **128**, 97
Bruckert, E., A. von Eckardstein, H. Funke, I. Beucler, H. Wiebusch, G. Turpin, G. Assmann, The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I_{Milano} **128**, 121
Brugada, R., A.J. Marian, A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction **128**, 107

Calzada, C., K.R. Bruckdorfer, C.A. Rice-Evans, The influence of antioxidant nutrients on platelet function in healthy volunteers **128**, 97

Dabach, Y., see Friedman, G. **128**, 67
Dean, R.T., see Garner, B. **128**, 47
Després, J.-P., see Vohl, M.-C. **128**, 183

Ebeling, T., see Ilmonen, M. **128**, 191
Ehnholm, C., see Knudsen, P. **128**, 165
Ehnholm, C., see Tilly-Kiesi, M. **128**, 213
Ehnholm, S., see Knudsen, P. **128**, 165
Esaki, T., T. Hayashi, E. Muto, K. Yamada, M. Kuzuya, A. Iguchi, Expression of inducible nitric oxide synthase in T lymphocytes and macrophages of cholesterol-fed rabbits **128**, 39
Ezenwaka, C.E., A.O. Akanji, B.O. Akanji, N.C. Unwin, C.A. Adejuwon, The prevalence of insulin resistance and other cardiovascular disease risk factors in healthy elderly southwestern nigerians **128**, 201

Fagot-Campagna, A., K.M.V. Narayan, R.L. Hanson, G. Imperatore, B.V. Howard, R.G. Nelson, D.J. Pettitt, W.C. Knowler, Plasma lipoproteins and incidence of non-insulin-dependent diabetes mellitus in Pima Indians: protective effect of HDL cholesterol in women **128**, 113
Friedlander, Y., see Friedman, G. **128**, 67
Friedman, G., A. Ben-Yehuda, Y. Dabach, M. Ben-Naim, G. Hollander, O. Retter, Y. Friedlander, O. Stein, Y. Stein, Scavenger receptor activity and expression of apolipoprotein E mRNA in monocyte-derived macrophages of young and old healthy men **128**, 67
Funke, H., see Bruckert, E. **128**, 121
Funke, H., see Knudsen, P. **128**, 165

Garner, B., A. Baoutina, R.T. Dean, W. Jessup, Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by interferon-γ. Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression **128**, 47
Guldberg, P., see Nissen, H. **128**, 75
Gupta, R.S., see Schett, G. **128**, 27

Haas, U., see Teupser, D. **128**, 157
Halle, M., D. König, A. Berg, J. Keul, M.W. Baumstark, Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease **128**, 235
Hansen, A.B., see Nissen, H. **128**, 75
Hansen, T.S., see Nissen, H. **128**, 75
Hanson, R.L., see Fagot-Campagna, A. **128**, 113
Harsch, M., J.H. Braesen, A. Niendorf, Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year **128**, 139
Hayashi, T., see Esaki, T. **128**, 39
Hirose, N., see Homma, S. **128**, 85
Hixson, J.E., see Rainwater, D.L. **128**, 223
Hollander, G., see Friedman, G. **128**, 67
Homma, S., T. Ishii, S. Tsugane, N. Hirose, Different effects of hypertension and hypercholesterolemia on the natural history of aortic atherosclerosis by the stage of intimal lesions **128**, 85
Howard, B.V., see Fagot-Campagna, A. **128**, 113
Hørder, M., see Nissen, H. **128**, 75
Hussein, O., S. Schlezinger, M. Rosenblat, S. Keidar, M. Aviram, Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL **128**, 11

Ibrahim, S.F., see Stadler, R.W. **128**, 241
Iguchi, A., see Esaki, T. **128**, 39
Ilmonen, M., T. Ebeling, J. Viikari, J.-P. Ojala, M.J. Tikkanen, Screening of the 3′ two-thirds of the coding area of the apo B gene in Finnish hypercholesterolemic patients: Report of six new genetic variants **128**, 191
Imperatore, G., see Fagot-Campagna, A. **128**, 113
Ishii, T., see Homma, S. **128**, 85

Janus, E.D., see Tam, S.C.F. **128**, 175
Jessup, W., see Garner, B. **128**, 47

Kahri, J., see Tilly-Kiesi, M. **128**, 213
Kammerer, C.M., see Rainwater, D.L. **128**, 223
Keidar, S., see Hussein, O. **128**, 11
Keul, J., see Halle, M. **128**, 235
Kinukawa, N., see Nakamura, M. **128**, 149
Kishi, Y., see Watanabe, R. **128**, 19
Knowler, W.C., see Fagot-Campagna, A. **128**, 113
Knudsen, P., M. Antikainen, M. Uusi-Oukari, S. Ehnholm, S. Lahdenperä, A. Bensadoun, H. Funke, H. Wiebusch, G. Assmann, M.-R. Taskinen, C. Ehnholm, Heterozygous hepatic lipase deficiency, due to two missense mutations R186H and L334F, in the HL gene **128**, 165
König, D., see Halle, M. **128**, 235
Kothari, H.V., K.J. Poirier, W.H. Lee, Y. Satoh, Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters **128**, 59
Kuzuya, M., see Esaki, T. **128**, 39
Kwan, E.Y.W., see Tam, S.C.F. **128**, 175

Lahdenperä, S., see Knudsen, P. **128**, 165
Lamarche, B., see Vohl, M.-C. **128**, 183
Lees, R.S., see Stadler, R.W. **128**, 241
Lee, W.H., see Kothari, H.V. **128**, 59
Lip, G.Y.H., see Blann, A.D. **128**, 135
Low, L.C.K., see Tam, S.C.F. **128**, 175
Lupien, P.J., see Vohl, M.-C. **128**, 183

Man, R.Y.K., see Ren, S. **128**, 1
Marian, A.J., see Brugada, R. **128**, 107
Mayr, M., see Schett, G. **128**, 27
Metzler, B., see Schett, G. **128**, 27
Mizzen, L., see Schett, G. **128**, 27
Moorjani, S., see Vohl, M.-C. **128**, 183
Muto, E., see Esaki, T. **128**, 39

Nadeau, A., see Vohl, M.-C. **128**, 183
Nakamura, M., S. Abe, N. Kinukawa, Aortic medial necrosis with or without thrombosis in rabbits treated with Russell's viper venom and angiotensin II **128**, 149
Narayan, K.M.V., see Fagot-Campagna, A. **128**, 113
Nelson, R.G., see Fagot-Campagna, A. **128**, 113
Niederwieser, D., see Schett, G. **128**, 27
Niendorf, A., see Harsch, M. **128**, 139
Nissen, H., A.B. Hansen, P. Guldberg, N.E. Petersen, T.S. Hansen, M. Hørder, Detection and characterization of a novel splice mutation in the LDL receptor intron 12 resulting in two different mutant mRNA variants **128**, 75
Numano, F., see Watanabe, R. **128**, 19

Ojala, J.-P., see Ilmonen, M. **128**, 191

Packard, C.J., see Tilly-Kiesi, M. **128**, 213
Pang, R.W.C., see Tam, S.C.F. **128**, 175
Petersen, N.E., see Nissen, H. **128**, 75
Pettitt, D.J., see Fagot-Campagna, A. **128**, 113
Poirier, K.J., see Kothari, H.V. **128**, 59
Prud'homme, D., see Vohl, M.-C. **128**, 183

Rainwater, D.L., C.M. Kammerer, J.L. VandeBerg, J.E. Hixson, Characterization of the genetic elements controlling lipoprotein(a) concentrations in Mexican Americans. Evidence for at least three controlling elements linked to *LPA*, the locus encoding apolipoprotein(a) **128**, 223
Ren, S., R.Y.K. Man, A. Angel, G.X. Shen, Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells **128**, 1
Retter, O., see Friedman, G. **128**, 67
Rice-Evans, C.A., see Calzada, C. **128**, 97
Rosenblat, M., see Hussein, O. **128**, 11

Sakita, S.-y., see Watanabe, R. **128**, 19
Satoh, Y., see Kothari, H.V. **128**, 59
Schett, G., B. Metzler, M. Mayr, A. Amberger, D. Niederwieser, R.S. Gupta, L. Mizzen, Q. Xu, G. Wick, Macrophage-lysis mediated by autoantibodies to heat shock protein 65/60 **128**, 27

Schlezinger, S., see Hussein, O. **128**, 11
Seidel, D., see Teupser, D. **128**, 157
Shen, G.X., see Ren, S. **128**, 1
Shepherd, J., see Tilly-Kiesi, M. **128**, 213
Stadler, R.W., S.F. Ibrahim, R.S. Lees, Peripheral vasoactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporeal LDL precipitation (HELP) **128**, 241
Stein, O., see Friedman, G. **128**, 67
Stein, O., see Teupser, D. **128**, 157
Stein, Y., see Friedman, G. **128**, 67
Stein, Y., see Teupser, D. **128**, 157

Tam, S.C.F., R.W.C. Pang, E.D. Janus, E.Y.W. Kwan, L.C.K. Low, Growth hormone therapy transiently increases apolipoprotein(a) in short β-thalassaemia major children with normal growth hormone reserve **128**, 175
Taskinen, M.-R., see Knudsen, P. **128**, 165
Taskinen, M.-R., see Tilly-Kiesi, M. **128**, 213
Teupser, D., J. Thiery, U. Haas, O. Stein, Y. Stein, D. Seidel, Expression of vascular cell adhesion molecule-1 (VCAM-1) in the aortae of hypercholesterolemic rabbits with high (HAR) and low (LAR) atherosclerotic response **128**, 157
Thiery, J., see Teupser, D. **128**, 157
Tikkanen, M.J., see Ilmonen, M. **128**, 191
Tilly-Kiesi, M., C.J. Packard, J. Kahri, C. Ehnholm, J. Shepherd, M.-R. Taskinen, In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I($Lys_{107} \rightarrow 0$) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency **128**, 213
Tremblay, A., see Vohl, M.-C. **128**, 183
Tsugane, S., see Homma, S. **128**, 85
Turpin, G., see Bruckert, E. **128**, 121

Unwin, N.C., see Ezenwaka, C.E. **128**, 201
Uusi-Oukari, M., see Knudsen, P. **128**, 165

VandeBerg, J.L., see Rainwater, D.L. **128**, 223
Viikari, J., see Ilmonen, M. **128**, 191
Vohl, M.-C., B. Lamarche, J. Bergeron, S. Moorjani, D. Prud'homme, A. Nadeau, A. Tremblay, P.J. Lupien, C. Bouchard, J.-P. Després, The *Msp*I polymorphism of the apolipoprotein A-II gene as a modulator of the dyslipidemic state found in visceral obesity **128**, 183
von Eckardstein, A., see Bruckert, E. **128**, 121

Watanabe, R., Y. Kishi, S.-y. Sakita, F. Numano, Impaired NO release from bovine aortic endothelial cells exposed to activated platelets **128**, 19
Wick, G., see Schett, G. **128**, 27
Wiebusch, H., see Bruckert, E. **128**, 121
Wiebusch, H., see Knudsen, P. **128**, 165

Xu, Q., see Schett, G. **128**, 27

Yamada, K., see Esaki, T. **128**, 39

ELSEVIER

Atherosclerosis 128 (1997) 271–272

ATHEROSCLEROSIS

Subject index

Volume 128 (1997)

Acute myocardial infarction **128**, 149
Adhesion molecules **128**, 157
Africans **128**, 201
Age **128**, 201
Aging **128**, 67
Angiotensin II **128**, 149
Antibodies **128**, 27
Antioxidants **128**, 97
Aorta **128**, 85, 149
Apheresis **128**, 241
Apo A-II **128**, 183
Apo(a) isoforms **128**, 175
Apolipoprotein(a) **128**, 175, 223
Apolipoprotein A-I **128**, 121
Apolipoprotein A-$I_{107 \rightarrow 0}$ **128**, 213
Apolipoprotein A-I and apolipoprotein A-II kinetics **128**, 213
Apolipoprotein B gene **128**, 191
Apolipoprotein E **128**, 47
Apolipoprotein E mRNA **128**, 67
Arterial thrombosis **128**, 149
Arteriosclerosis **128**, 149
Atheroma **128**, 157
Atherosclerosis **128**, 27, 39, 67, 85, 135, 139, 235, 241
Autoimmunity **128**, 27
Autopsy study **128**, 85

Cardiovascular disease **128**, 201
Cell death **128**, 27
CETP **128**, 59
Cholesterol ester transfer protein **128**, 59
Coronary artery disease **128**, 75, 107
Coronary risk factors **128**, 235

Endolthelium **128**, 157
Endothelial cells **128**, 1, 135
Endothelium **128**, 19
Endothelium-derived relaxing factor **128**, 241

Familial hypoalphalipoproteinemia **128**, 121
Ferritin **128**, 235
Fluvastatin **128**, 11
Folic acid **128**, 107
Free fatty acids **128**, 183

Genetics **128**, 75, 107
Glucose **128**, 113
Golden Syrian hamster **128**, 59
Growth hormone therapy **128**, 175

HDL-cholesterol **128**, 59, 165
HDL cholesterol **128**, 183
Heat shock protein **128**, 27
Hepatic lipase **128**, 165
Histomorphometry **128**, 85
HMG-CoA reductase inhibitor **128**, 139
Homocysteine **128**, 107
Human volunteer study **128**, 97
Hypercholesterolemia **128**, 11, 191, 241
Hyperinsulinemia **128**, 183
Hypertension **128**, 85

Incidence **128**, 113
iNOS **128**, 39
Insulin resistance **128**, 113, 201
Insulin resistance syndrome **128**, 235
Interferon-γ **128**, 47
Intimal thickness **128**, 85
Isoflavan **128**, 59

LDL lipid peroxidation **128**, 11
LDL subfractions **128**, 235
Lipoprotein(a) **128**, 1, 223
Lipoprotein(AI w AII) deficiency **128**, 213
Lipoprotein lipase **128**, 47
Lipoproteins **128**, 113, 175
Low density lipoprotein receptor **128**, 75
Low density lipoprotein receptor-related protein **128**, 47
Low HDL cholesterol **128**, 213
LPA locus **128**, 223

Macrophage-foam cell **128**, 47
Macrophages **128**, 39, 157

Medial necrosis **128**, 149
Mexican Americans **128**, 223
Modified LDL **128**, 67
Morphometric analysis **128**, 139
Mutation **128**, 165
Myocardial infarction **128**, 107

Necrotic core **128**, 39
Nitric oxide **128**, 19

Oxidative modification **128**, 1

Plasminogen activator inhibitor-1 **128**, 1
Platelet activation **128**, 135
Platelet function **128**, 97
Platelets **128**, 19, 97
Pravastatin sodium **128**, 139
Prostacyclin **128**, 19

Risk factor **128**, 107

Scavenger receptor **128**, 67
Serum cholesterol **128**, 85
Sex **128**, 113
SMC **128**, 157
Soluble P-selectin **128**, 135
SSCP analysis **128**, 191
Statins **128**, 11
Stress proteins **128**, 27

T cells **128**, 39
β-Thalassemia major **128**, 175
Thrombosis **128**, 135
Triglycerides **128**, 165
Tropical medicine **128**, 201

Ultrasound **128**, 241

Visceral obesity **128**, 183
von Willebrand factor **128**, 135

WHHL rabbits **128**, 139, 149